Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Oct 22

PMID 34676211

Citations 14

Authors

Ze-Bing Song

Yang Yu

Guo-Pei Zhang

Shao-Qiang Li

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the major cancer-related deaths worldwide. Genomic instability is correlated with the prognosis of cancers. A biomarker associated with genomic instability might be effective to predict the prognosis of HCC. In the present study, data of HCC patients from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases were used. A total of 370 HCC patients from the TCGA database were randomly classified into a training set and a test set. A prognostic signature of the training set based on nine overall survival (OS)-related genomic instability-derived genes (SLCO2A1, RPS6KA2, EPHB6, SLC2A5, PDZD4, CST2, MARVELD1, MAGEA6, and SEMA6A) was constructed, which was validated in the test and TCGA and ICGC sets. This prognostic signature showed more accurate prediction for prognosis of HCC compared with tumor grade, pathological stage, and four published signatures. Cox multivariate analysis revealed that the risk score could be an independent prognostic factor of HCC. A nomogram that combines pathological stage and risk score performed well compared with an ideal model. Ultimately, paired differential expression profiles of genes in the prognostic signature were validated at mRNA and protein level using HCC and paratumor tissues obtained from our institute. Taken together, we constructed and validated a genomic instability-derived gene prognostic signature, which can help to predict the OS of HCC and help us to explore the potential therapeutic targets of HCC.

Citing Articles

Pan-cancer and experimental analyses reveal the immunotherapeutic significance of CST2 and its association with stomach adenocarcinoma proliferation and metastasis.

Huang D, Li J, He Z, Liang W, Zhong L, Huang J Front Immunol. 2025; 15:1466806.

PMID: 39926600 PMC: 11802563. DOI: 10.3389/fimmu.2024.1466806.

Urgent need for prognostic markers for hepatocellular carcinoma in the light of genomic instability and non-coding RNA signatures.

Velikova T, Gulinac M World J Gastrointest Surg. 2024; 16(10):3087-3090.

PMID: 39575279 PMC: 11577397. DOI: 10.4240/wjgs.v16.i10.3087.

Advancing prognostic understanding in hepatocellular carcinoma through the integration of genomic instability and lncRNA signatures: GILncSig model.

Bocchetti M, Misso G, Zappavigna S, Scrima M, Caraglia M, Pentimalli F World J Gastrointest Surg. 2024; 16(9):2774-2777.

PMID: 39351545 PMC: 11438822. DOI: 10.4240/wjgs.v16.i9.2774.

Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.

Chen E, Zou Z, Wang R, Liu J, Peng Z, Gan Z Front Immunol. 2024; 15:1244392.

PMID: 38694506 PMC: 11061862. DOI: 10.3389/fimmu.2024.1244392.

Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets.

Liu Y, Li X, Yang J, Chen S, Zhu C, Shi Y Heliyon. 2024; 10(8):e29655.

PMID: 38655365 PMC: 11036058. DOI: 10.1016/j.heliyon.2024.e29655.

References

Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Katai H . The genomic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer. Gastroenterology. 2003; 125(5):1330-40. DOI: 10.1016/j.gastro.2003.07.006. View

Bignone P, Lee K, Liu Y, Emilion G, Finch J, Soosay A . RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene. 2006; 26(5):683-700. DOI: 10.1038/sj.onc.1209827. View

Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y . Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas. Oncogene. 2004; 23(32):5551-7. DOI: 10.1038/sj.onc.1207710. View

Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K . DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035):864-70. DOI: 10.1038/nature03482. View

Liu G, Zeng H, Zhang C, Xu J . Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int. 2019; 19:138. PMC: 6528264. DOI: 10.1186/s12935-019-0858-2. View

Yu Y, Zhang Y, Hu J, Zhang H, Wang S, Han F . MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma. Cancer Sci. 2012; 103(4):716-22. PMC: 7659181. DOI: 10.1111/j.1349-7006.2012.02220.x. View

Wang T, Wang G, Zhang X, Wu D, Yang L, Wang G . The expression of miRNAs is associated with tumour genome instability and predicts the outcome of ovarian cancer patients treated with platinum agents. Sci Rep. 2017; 7(1):14736. PMC: 5677022. DOI: 10.1038/s41598-017-12259-w. View

Mettu R, Wan Y, Habermann J, Ried T, Guo N . A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers. 2010; 25(4):219-28. PMC: 3155635. DOI: 10.5301/jbm.2010.6079. View

Habermann J, Doering J, Hautaniemi S, Roblick U, Bundgen N, Nicorici D . The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer. 2008; 124(7):1552-64. PMC: 2707256. DOI: 10.1002/ijc.24017. View

10.

Zhao P, Huang J, Zhang D, Zhang D, Wang F, Qu Y . SLC2A5 overexpression in childhood philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2018; 183(2):242-250. DOI: 10.1111/bjh.15580. View

11.

Bao S, Zhao H, Yuan J, Fan D, Zhang Z, Su J . Computational identification of mutator-derived lncRNA signatures of genome instability for improving the clinical outcome of cancers: a case study in breast cancer. Brief Bioinform. 2019; 21(5):1742-1755. DOI: 10.1093/bib/bbz118. View

12.

Egland K, Vincent J, Strausberg R, Lee B, Pastan I . Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc Natl Acad Sci U S A. 2003; 100(3):1099-104. PMC: 298733. DOI: 10.1073/pnas.0337425100. View

13.

Zhang W, Wang Y, Tan D, Xing C . Cystatin 2 leads to a worse prognosis in patients with gastric cancer. J Biol Regul Homeost Agents. 2020; 34(6):2059-2067. DOI: 10.23812/20-293-A. View

14.

Slattery M, Lundgreen A, Herrick J, Wolff R . Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res. 2010; 706(1-2):13-20. PMC: 3038588. DOI: 10.1016/j.mrfmmm.2010.10.005. View

15.

Kronenwett U, Ploner A, Zetterberg A, Bergh J, Hall P, Auer G . Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1630-5. DOI: 10.1158/1055-9965.EPI-06-0080. View

16.

Chen L, Liao C, Lai L, Tsai M, Chuang E . Semaphorin 6A Attenuates the Migration Capability of Lung Cancer Cells via the NRF2/HMOX1 Axis. Sci Rep. 2019; 9(1):13302. PMC: 6746772. DOI: 10.1038/s41598-019-49874-8. View

17.

Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F . Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med. 2020; 18(1):67. PMC: 7011553. DOI: 10.1186/s12967-020-02255-6. View

18.

Jachimowicz R, Beleggia F, Isensee J, Velpula B, Goergens J, Bustos M . UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell. 2019; 176(3):505-519.e22. DOI: 10.1016/j.cell.2018.11.024. View

19.

. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell. 1997; 90(3):403-4. DOI: 10.1016/s0092-8674(00)80500-0. View

20.

Weng Y, Fan X, Bai Y, Wang S, Huang H, Yang H . promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. Cell Death Discov. 2018; 4:38. PMC: 5841403. DOI: 10.1038/s41420-018-0038-5. View